Last reviewed · How we verify

NCT04354519: UKMSRCV19

The United Kingdom Multiple Sclerosis Register Covid-19 Substudy

Status unknown Last updated 17 August 2021
What this trial tests

trial in Multiple Sclerosis in 3,000 participants. Status unknown.

Timeline
14 March 2020
Primary endpoint
14 July 2022
14 July 2022

Quick facts

Lead sponsorSwansea University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment3,000
Start date14 March 2020
Primary completion14 July 2022
Estimated completion14 July 2022
Sites1 location across United Kingdom

Conditions studied

Sponsor

Swansea University

Who can join

18 and older, any sex, with Multiple Sclerosis or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.
    Amor S, Baker D, Khoury SJ, Schmierer K, et al · · 2020 · cited 37× · PMID 32383812 · DOI 10.1002/ana.25770
  2. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
    Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, et al · · 2021 · cited 35× · PMID 34010764 · DOI 10.1016/j.msard.2021.102939
  3. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
    Evangelou N, Garjani A, dasNair R, Hunter R, et al · · 2020 · cited 31× · PMID 32855290 · DOI 10.1136/jnnp-2020-324449
  4. Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register.
    Garjani A, Middleton RM, Nicholas R, Evangelou N. · · 2022 · cited 30× · PMID 34848503 · DOI 10.1212/nxi.0000000000001118
  5. Neuropsychiatric Disorders and COVID-19: What We Know So Far.
    Majolo F, Silva GLD, Vieira L, Anli C, et al · · 2021 · cited 12× · PMID 34577633 · DOI 10.3390/ph14090933
  6. Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study.
    das Nair R, Hunter R, Garjani A, Middleton RM, et al · · 2021 · cited 3× · PMID 34135052 · DOI 10.1136/bmjopen-2021-048788
  7. Pre-existing anxiety, depression, and neurological disability is associated with long COVID: A prospective and longitudinal cohort of the United Kingdom Multiple Sclerosis Register
    Garjani A, Middleton RM, Nicholas R, Evangelou N. · · 2021 · DOI 10.1101/2021.06.25.21259256
  8. COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies
    Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, et al · · 2021 · DOI 10.1101/2021.03.08.21253141

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Swansea University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04354519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing